Last checked at 
(Sharecast News) - Neuroscience data analytics company Ixico has executed a contract to provide neuroimaging services that would support a phase 1b and 2 clinical trial for Huntington's disease, it announced on Friday.
The AIM-traded firm said the contract would build on its existing relationship with the sponsor, with which they contracted a prior safety and efficacy trial in 2019.
It said that, by deploying imaging biomarker solutions in early phase studies, the company would enable the sponsor to accelerate research and development decision making, and maximise the value of their drug development pipelines.
The contract was included in management's expectations of performance for the current financial year, but added to the company's order book.
"Huntington's disease is a devastating rare neurological condition with unmet medical needs," said chief commercial officer Lammert Albers.
"Ixico has worked on numerous HD clinical studies since 2007 and is pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease.
"Our services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development."
At 1206 GMT, shares in Ixico were down 3.25% at 119p.
24 May 2022 12:24
IN BRIEF: Ixico interim profit falls; warns on cancelled client trials
Ixico PLC - London-based medical imaging company - Posts lower interim profit for the half year ended March 31. Pretax profit falls to GBP201,000 from GBP635,000 a year ago due to the impact of cancelled client trials. Revenue drops to GBP3.9 million from GBP4.9 million.
Read more